Drug Profile
Menstrual blood derived mesenchymal stem cell therapy - S-Evans
Alternative Names: C'elle menstrual stem cells; Human menstrual blood derived mesenchymal stem cell therapy - S-Evans; MenSCLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Cryo-Cell International
- Developer S-Evans Biosciences; Zhejiang University
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute lung injury; Liver cirrhosis; Type 1 diabetes mellitus
Most Recent Events
- 01 Sep 2017 No recent reports on development identified - Phase-I/II for Acute lung injury in China (IV)
- 01 Sep 2017 No recent reports on development identified - Phase-I/II for Cirrhosis in China (IV)
- 01 Sep 2017 No recent reports on development identified - Phase-I/II for Type-1 diabetes mellitus in China (IV)